Novartis gene therapy would be cost effective up to $900,000: U.S. group

(Reuters) – An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments.

FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann

The Boston-based Institute for Clinical and Economic Review (ICER) made the determination using a commonly cited cost-effectiveness threshold that values each “quality-adjusted life year” (QALY) gained at $100,000 to $150,000.

If each QALY gained were assessed at $500,000, ICER found the gene therapy, Zolgensma, would be cost effective at just over $5 million.

Novartis has said the price will be determined in negotiations with health plans, but it believes the gene therapy would be cost effective at $4 million to $5 million as a one-time treatment.

The company said in an emailed statement on Friday that “both the rare disease community and various governmental bodies” suggest that $500,000 per QALY “is the appropriate standard to protect vulnerable populations and allow access to innovative, transformational therapies.”

SMA can lead to paralysis, breathing difficulty and death. It is the leading genetic cause of death in infants.

Gene therapies use engineered viruses to carry healthy genetic material into a person’s cells to replace faulty or mutated genes that cause a disease or condition.

ICER also found that Spinraza, Biogen Inc’s SMA treatment would require a substantial price decrease to be considered cost effective. Spinraza’s current list price is $750,000 for the initial year and $375,000 per year thereafter.

Biogen noted that Zolgensma is experimental and has reported data for only 15 patients, compared with Spinraza’s track record of use by more than 6,600 patients. Spinraza is considered by Wall Street to be one of Biogen’s most important growth drivers.

“The promise of gene therapy in general is that it would be once and done … but that is uncertain at this point,” Biogen Chief Medical Officer Alfred Sandrock told Reuters.

“Spinraza is still a very viable option for babies with SMA. For children, teenagers and adults it may be the only option open to them,” Sandrock said.

Spinraza was approved in 2016 to treat SMA in children and adults.

The U.S. Food and Drug Administration is expected to decide sometime in May whether to approve Zolgensma, which has been studied in infants with SMA.

ICER’s assessments have become increasingly influential in U.S. drug price negotiations and are taken into consideration by insurers making decisions about patient access to treatments.

Using an alternate measure known as “life years gained” (LYG), ICER found the Novartis gene therapy cost effective at a price as high as $1.5 million.

ICER found that Spinraza, when used for patients who do not yet show symptoms, would have value at up to $130,000 for the first year and $65,000 for each successive year. Based on the LYG measurement, the price could be as high as $82,000 during the initial year and $41,000 per year thereafter, according to the ICER report.

At the QALY value of $500,000, Spinraza was seen by ICER as cost-effective at $264,000 per year.

Reporting By Deena Beasley; Editing by Bill Berkrot

Source

more recommended stories

  • Senator Gillibrand wants insurance to pay for fertility treatments

    WASHINGTON (Reuters) – U.S. Democratic presidential.

  • Hundreds rally at U.S. Supreme Court, calling state abortion bans as step backward

    WASHINGTON (Reuters) – Abortion-rights campaigners, including.

  • French court says doctors must resume life support for paralyzed patient

    STRASBOURG, France (Reuters) – A French.

  • Missouri follows Alabama by passing restrictive abortion bill

    (Reuters) – Missouri lawmakers passed a.

  • Too much screen time tied to school problems even in little kids

    (Reuters Health) – Kindergarteners who get.

  • Smokers have higher risk for multiple strokes

    (Reuters Health) – Smokers who have.

  • Missouri assembly passes restrictive abortion bill, days after Alabama

    (Reuters) – The lower house of.

  • Missouri Senate passes bill to ban abortions after eight weeks

    (Reuters) – Missouri’s Senate passed a.

  • Alabama governor signs strictest U.S. abortion ban into law

    (Reuters) – Alabama’s governor signed a.

  • Alabama Senate bans nearly all abortions, including rape cases

    (Reuters) – Alabama’s state Senate passed.

  • Israel regulator warns of medical cannabis bubble, eyes Australia pact

    JERUSALEM (Reuters) – Medical cannabis could.

  • U.S. measles outbreak grows with 75 new cases, mostly in New York

    (Reuters) – U.S. health authorities recorded.

  • Teva Pharm CFO says company did not conspire to fix prices

    FILE PHOTO: The logo of Teva.

  • U.S. states accuse Teva, other drugmakers, of price-fixing: lawsuit

    WASHINGTON (Reuters) – U.S. states filed.

  • Exclusive: Philip Morris suspends social media campaign after Reuters exposes young ‘influencers’

    (Reuters) – Cigarette maker Philip Morris.

  • Hong Kong reports African swine fever case

    HONG KONG (Reuters) – Hong Kong.

  • Alabama Senate delays vote on strict anti-abortion bill

    (Reuters) – Alabama’s state Senate on.

  • Denver votes to become first U.S. city to decriminalize ‘magic mushrooms’

    Psilocybin or “magic mushrooms” are seen.

  • AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

    The company logo for pharmaceutical company.

  • Denver to vote on decriminalizing ‘magic mushrooms’

    FILE PHOTO: Boxes containing magic mushrooms.

  • Trans teens face higher sexual assault risk when schools restrict bathrooms

    (Reuters Health) – Transgender adolescents may.

  • U.S. doctors use medical records to fight measles outbreak

    CHICAGO (Reuters) – U.S. doctors are.

  • UK’s Vectura wins patent infringement case against GlaxoSmithKline in U.S

    (Reuters) – British drugmaker Vectura Group.

  • Tyson Foods recalls almost 12 million pounds of chicken strips over contamination fears

    (Reuters) – Tyson Foods Inc significantly.

  • Monstrous rumors stoke hostility to Pakistan’s anti-polio drive

    PESHAWAR, Pakistan (Reuters) – His bearded.

  • U.S. health agency finalizes conscience and religious freedom rule

    WASHINGTON (Reuters) – The U.S. Department.

  • Medication use drops when local drugstores close

    (Reuters Health) – People are less.

  • EPA says popular weed killer glyphosate is not a carcinogen

    CHICAGO (Reuters) – The U.S. Environmental.

  • Novartis’s Sandoz strikes deal for biosimilar of Herceptin

    FILE PHOTO: Swiss drugmaker Novartis’ logo.

  • U.S. measles outbreak triggers quarantine at two Los Angeles universities

    LOS ANGELES (Reuters) – A nationwide.

  • U.S. measles outbreak raises questions about immunity in adults

    (Reuters) – Adults in the United.

  • FDA approves expanded label for Regeneron/Sanofi’s cholesterol drug

    (Reuters) – The U.S. Food and.